Background:
Several studies have shown that the intake of N. sativa has a beneficial
effect on metabolic syndrome and related disorders. In this meta-analysis, our primary objective
was to assess the impact of Nigella sativa consumption on inflammation and oxidative stress
biomarkers among individuals diagnosed with metabolic syndrome and its associated conditions.
Methods:
Our search was conducted on prominent online databases such as Web of Science,
Scopus, PubMed, and EMBASE, utilizing relevant keywords until August 2023.
Results:
This meta-analysis was performed on 16 RCTs comprising 1033 participants. Our results
showed that intake of nigella sativa significantly decreased CRP [SMD: -0.60; (95% CI:
from -0.96 to -0.23); P = 0.00], TNF-α [SMD: -0.53; (95% CI: from -0.74 to -0.53); P = 0.00];
IL-6 [SMD: -0.54 ; (95% CI: from -1.01 to -0.07); P = 0.02], and MDA: [SMD: -1.28; (95% CI:
from -2.11 to -0.46); P = 0.00] levels. In addition, SOD: [SMD: 1.35; (95% CI, from 0.77 to
1.93); P = 0.00] and TAC [SMD: 2.82; (95% CI, from 0.55 to 5.084); P = 0.01] levels significantly
increased in the intervention group compared to the placebo group.
Conclusion:
Our results showed that THE consumption of N. sativa could be associated with
improved oxidative stress and inflammation in patients with metabolic syndrome and related
disorders.